NCT00439868View on ClinicalTrials.gov

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

PHASE1CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

February 16, 2007

Primary Completion Date

June 8, 2007

Study Completion Date

June 8, 2007

Conditions

Depressive Disorder

Interventions

DRUG

WellbutrinXL

WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.

DRUG

placebo

Matching placebo tablets to WELLBUTRIN XL.

Trial Locations (1)

32605

GSK Investigational Site, Gainesville

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY